

BIOCEPT, INC.
5810 Nancy Ridge Drive
San Diego, CA 92121

May 21, 2018

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Biocept, Inc.
Registration Statement on Form S-3
Filed May 15, 2018
File No. 333-224946

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the U.S. Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on May 24, 2018 or as soon thereafter as is practicable.

The undersigned registrant hereby acknowledges that:

- should the Commission or its staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
 - the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
 - the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
-

Very truly yours,

BIOCEPT, INC.

By: /s/ Timothy C. Kennedy

Timothy C. Kennedy

Chief Financial Officer, Senior VP of Operations and Secretary

2.